Sarepta Provides New Elevidys Safety Data, Reveals Zero Ambulatory Deaths
Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory patients with Duchenne muscular dystrophy.Read more:
biospace.comBiotechnology